Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health
October 10 2023 - 8:15AM
Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading
developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, welcomes the recent
decision by the High Court of Kenya. The court has struck out both
the interim application and the entire lawsuit filed by Gamma
Zenith Kenya Limited against Trinity Biotech, Radiance
Pharmaceutical, the Kenyan Ministry of Health, and the Kenyan
Attorney General, that sought to prevent the Kenyan Ministry of
Health's procurement of TrinScreen HIV test kits. The High Court
also discharged the interim orders that previously placed temporary
restrictions on the procurement of TrinScreen HIV tests.
This court ruling marks a positive development
for both public health in Kenya and Trinity Biotech. It signifies
the removal of the legal barriers that had hindered the sale of
TrinScreen HIV test kits to the Kenyan Ministry of Health.
Consequently, Trinity Biotech is now able to proceed with supplying
TrinScreen HIV in Kenya. Trinity Biotech expects to imminently
receive TrinScreen HIV orders for the new Kenyan HIV rapid testing
algorithm.
The Kenyan HIV screening programme is one of the
largest in Africa, with an estimated annual number of screening
tests of approximately 10 million.
A separate legal case against the Kenyan
Ministry of Health and others, which challenged the new HIV rapid
testing algorithm, was scheduled for a ruling on October 5, 2023.
However, the ruling was not delivered as the trial judge was not
available. The ruling will be delivered on notice, meaning that the
court will issue its decision at a later date. It is important to
highlight that, at present, the Company believes that there are no
existing court orders that prohibit the Kenyan Ministry of Health
from purchasing TrinScreen HIV test kits.
Forward-Looking Statements
Certain statements made in this release that are
not historical are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
“estimate”, “project”, “intend”, “expect”, “believe” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks
and uncertainties. Many factors could cause the actual results,
performance or achievements of Trinity Biotech to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements,
including, but not limited to, the results of research and
development efforts, risks associated with the outbreak and global
spread of the coronavirus (COVID-19), the effect of regulation by
the U.S. Food and Drug Administration and other agencies, the
impact of competitive products, product development
commercialization and technological difficulties. For additional
information regarding these and other risks and uncertainties
associated with Trinity Biotech’s business, reference is made to
our reports filed from time to time with the U.S. Securities and
Exchange Commission.
About Trinity Biotech Plc
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com.
Contact: |
Trinity Biotech plc |
|
Mícheál Roche |
|
(353)-1-2769800 |
|
E-mail:
investorrelations@trinitybiotech.com |
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024